SYRE vs. PCRX, MIRM, COLL, BLTE, PRTA, MNKD, GYRE, IRWD, VRNA, and ABCL
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Pacira BioSciences (PCRX), Mirum Pharmaceuticals (MIRM), Collegium Pharmaceutical (COLL), Belite Bio (BLTE), Prothena (PRTA), MannKind (MNKD), Gyre Therapeutics (GYRE), Ironwood Pharmaceuticals (IRWD), Verona Pharma (VRNA), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
Pacira BioSciences (NASDAQ:PCRX) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.
Pacira BioSciences currently has a consensus target price of $47.40, indicating a potential upside of 53.80%. Spyre Therapeutics has a consensus target price of $43.17, indicating a potential upside of 14.20%. Given Spyre Therapeutics' higher probable upside, analysts clearly believe Pacira BioSciences is more favorable than Spyre Therapeutics.
Pacira BioSciences has a net margin of 10.34% compared to Pacira BioSciences' net margin of 0.00%. Spyre Therapeutics' return on equity of 12.98% beat Pacira BioSciences' return on equity.
Pacira BioSciences received 799 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 71.81% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the S&P 500.
99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Pacira BioSciences has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Spyre Therapeutics had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 8 mentions for Spyre Therapeutics and 4 mentions for Pacira BioSciences. Spyre Therapeutics' average media sentiment score of 0.93 beat Pacira BioSciences' score of 0.76 indicating that Pacira BioSciences is being referred to more favorably in the media.
Summary
Pacira BioSciences beats Spyre Therapeutics on 13 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
